Matching articles for "Perseris"
Weltruza — A Once-Monthly Subcutaneous Formulation of Olanzapine
The Medical Letter on Drugs and Therapeutics • November 23, 2026; (Issue 1768)
Weltruza (Teva), a once-monthly subcutaneous (SC)
formulation of the second-generation antipsychotic drug
olanzapine, has been approved by the FDA for treatment of
schizophrenia in adults. A long-acting...
Weltruza (Teva), a once-monthly subcutaneous (SC)
formulation of the second-generation antipsychotic drug
olanzapine, has been approved by the FDA for treatment of
schizophrenia in adults. A long-acting intramuscular (IM)
formulation of olanzapine (Zyprexa Relprevv) is approved
for the same indication.
In Brief: Three New Injectable Antipsychotic Drugs
The Medical Letter on Drugs and Therapeutics • December 25, 2023; (Issue 1692)
Three extended-release injectable formulations of
second-generation antipsychotic drugs — two of
risperidone (Rykindo, Uzedy) and one of aripiprazole
(Abilify Asimtufii) — have been approved by the...
Three extended-release injectable formulations of
second-generation antipsychotic drugs — two of
risperidone (Rykindo, Uzedy) and one of aripiprazole
(Abilify Asimtufii) — have been approved by the FDA
for treatment of schizophrenia in adults. Rykindo and
Abilify Asimtufii are also approved for maintenance
treatment of bipolar I disorder in adults. Other
extended-release injectable formulations of
risperidone and aripiprazole have been available in
the US for years (see Table 1).